Stockhub

Intech Biopharm Corporation

Revision as of 00:38, 28 September 2022 by 87.224.91.72 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Intech Biopharm Corporation focuses on developing and manufacturing generic drugs to treat respiratory diseases. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and chronic pulmonary obstructive disease; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SY...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

Intech Biopharm Corporation focuses on developing and manufacturing generic drugs to treat respiratory diseases. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and chronic pulmonary obstructive disease; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=Intech_Biopharm_Corporation&oldid=97034"